Autoreactive B cells remain active despite clinical disease control in rheumatoid arthritis
ACPA<sup>+</sup> MBCs remain active despite clinical disease control in patients with RA across a range of interventions. This persistent activity indicates the absence of immunological remission and might explain why ACPA<sup>+</sup> patients rarely reach sustained drug-free remission and frequently flare upon drug tapering.
Authors
- Arieke S. B. Kampstra (ORCID: https://orcid.org/0000-0001-8840-7443)
- Hans Ulrich Scherer (ORCID: https://orcid.org/0000-0002-5700-5617)
- Joost G.K. van der Hem (ORCID: https://orcid.org/0000-0003-3111-4249)
- René E. M. Toes (ORCID: https://orcid.org/0000-0002-9618-6414)
- T. Huizinga (ORCID: https://orcid.org/0000-0001-7033-7520)
- Sam Neppelenbroek (ORCID: https://orcid.org/0000-0002-9582-2837)
- N. Blomberg
Institutions
- Leiden University Medical Center (NL)
Publication Details
- Journal
- Journal of Autoimmunity
- Published
- 2024-09-28
- DOI
- https://doi.org/10.1016/j.jaut.2024.103320
- Citations
- 6
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 2.43
Funders
- Eli Lilly and Company
- Pfizer
- Health~Holland
- Universiteit Leiden
- ZonMw
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
- Leids Universitair Medisch Centrum
- ReumaNederland
- Innovative Medicines Initiative
- Dutch Arthritis Association
- HORIZON EUROPE European Research Council